Novartis and Ionis Pharmaceuticals Face Setback in Pelacarsen Trial
Carlsbad, California — September 4, 2026 Ionis Pharmaceuticals and partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON...
Cardiovascular Outcomes
Advertisement
Alnylam Presents ATTR-CM Data at ESC Congress 2026
Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...
Amarin Reports Potential Legacy Effect of Icosapent Ethyl in New REDUCE-IT Analysis
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
Novo Nordisk Reports ZEUS Phase 3 Results for Ziltivekimab
BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...
Advertisement
